Skip to main content

OptiBiotix adds further level of protection with new patent filings

OptiBiotix adds further level of protection with new patent filings

OptiBiotix Health plc (LON:OPTI) has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.

The new patents reflect:-
· The success of its human studies designed to establish safety and efficacy on its capsular food supplement to reduce cholesterol
· The success of manufacturing studies designed to identify maximum production yields and volumes on its cholesterol reducing strain
· The identification of additional health benefits (hypertension reduction) shown by its cholesterol reducing strain

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the filing of these patents which add a further level of protection and value to our cholesterol reducing product. We believe these patents will further enhance the value proposition and negotiating position with commercial partners and make a significant contribution to building a successful and sustainable business for shareholders.”

See article in full at DirectorsTalkInterviews.com